Objective
This project investigates additional risk classification and best practice video instructions to each drug in the Swedish Formulary for Paediatric Medicines ePed [1], with ePed-ID 1417 vancomycin intravenous infusion 5 mg/mL as an example. (Fig 1).

Method
This project is part of the Swedish National Pharmaceutical Strategy [2] and consists of four work-packages during 2017-2018,
1) Risk assessment developed by EDQM [3]
2) Usage of video recording to assess reconstitution in six different paediatric settings
3) Identification of best practice by a Delphi process
4) Recording of professional videos for instruction purposes.

Results
Six paediatric centers contributed to the investigation of 100 of 630 ePed-ID during four months in 2017. Using vancomycin as an example, two centers order Ready To Use (RTU) to lower the residual risk. Four centers use closed-systems, and three centers added risk reducing strategies from a hood or forced ventilation. By observing the recorded videos (Fig 2), different strategies were present, e.g. additional protective clothing and processes in centers with non-validated closed system. The risk assessment (Tab 1) will result in three videos for instruction purposes regarding vancomycin;
1) RTU
2) validated closed-system reconstitution
3) non-validated closed-system reconstitution with protective clothing and forced ventilation

Discussion
The use of the EDQM risk assessment by analyzing video recordings resulted in both major and minor findings. The major findings are carried through a Delphi process and the best practice identified will be processed into an educational video platform.

References and acknowledgements
1. https://www.eped.se [In Swedish]
2. Financial support from The Swedish National Pharmaceutical Strategy

Conclusions
• Hospitals act with different risk reducing strategies
• The residual risk of reconstitution can easily be captured by video imaging
• All instructions in the Swedish Formulary for Paediatric Medicines (ePed) is to be risk assessed
• Suggested risk reducing strategies is carried through a Delphi process
• The Delphi consensus of risk reducing strategies is used to produce video instructions for an educational video platform

Table 1: Risk assessment and risk reducing strategies for ePed-ID 1417 vancomycin intravenous infusion 5 mg/mL with or without the use of Ready To Use (RTU) products as a risk reducing strategy. This assessment have so far been carried out for 100 ePed-ID out of 630.

Project coordinator (appointed by the Swedish Medical Association)
Per Nydert
E-mail: per.nydert@sll.se
Astrid Lindgren Childrens Hospital
171 76 Stockholm, Sweden